NCT04965597 2026-03-09
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
Fred Hutchinson Cancer Center
Phase 2 Completed
Clinical Trials
10 trialsNCT03961919 2023-11-18
FLAT-Auto
IRCCS San Raffaele
Phase 2 Completed
NCT00796068 2023-02-17
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00860574 2021-06-22
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT02333058 2020-05-04
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
medac GmbH
Phase 2 Completed
NCT00427999 2016-11-21
INV342
Novartis
Phase 2 Completed
NCT01772953 2016-10-12
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
Center for International Blood and Marrow Transplant Research
Phase 2 Completed
NCT00491634 2015-12-02
Treosulfan-based Conditioning for Transplantation in AML/MDS
Sheba Medical Center
Phase 2 Completed
NCT01063660 2010-02-05
Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)
medac GmbH
Phase 2 Completed
NCT01062490 2010-02-04
Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)
medac GmbH
Phase 2 Completed